{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,29]],"date-time":"2026-09-29T23:23:01Z","timestamp":1790724181282,"version":"4.1.0"},"reference-count":24,"publisher":"Wiley","issue":"3","license":[{"start":{"date-parts":[[2018,2,8]],"date-time":"2018-02-08T00:00:00Z","timestamp":1518048000000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/onlinelibrary.wiley.com\/termsAndConditions#vor"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Biopharm &amp; Drug Disp"],"published-print":{"date-parts":[[2018,3]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:p><jats:italic>Terminalia arjuna<\/jats:italic> (<jats:italic>T. arjuna<\/jats:italic>) is an Indian medicinal plant belonging to the family Combretaceae and possesses numerous therapeutic activities including its immense cardioprotective activity. In the present work, a methanolic bark extract of <jats:italic>T. arjuna<\/jats:italic> was evaluated for CYP3A and CYP2D inhibition potential in rat liver microsomes (RLM). Further, the methanolic bark extract was fractionated successively using increasing polarity solvents starting with petroleum ether, chloroform, ethyl acetate and <jats:italic>n<\/jats:italic>\u2010butanol. The fractions so obtained were also evaluated for their CYP3A and CYP2D inhibition potential. Probe substrates testosterone and dextromethorphan were used for CYP3A and CYP2D respectively. The IC<jats:sub>50<\/jats:sub> values for the methanolic extract and the fractions were found to be less than 50\u00a0\u03bcg\/ml in RLM for both CYP3A and CYP2D isoenzymes. The most potent <jats:italic>n<\/jats:italic>\u2010butanol fraction was further fractionated with column chromatography to isolate the highest active constituent responsible for the activity. Fraction 4 of the <jats:italic>n<\/jats:italic>\u2010butanol extract was the most potent fraction with IC<jats:sub>50<\/jats:sub> values of 5.64 \u00b1 0.735\u00a0\u03bcg\/ml and 16.63 \u00b1 0.879\u00a0\u03bcg\/ml for CYP3A and CYP2D in RLM, respectively. Therefore, <jats:italic>in vitro<\/jats:italic> data indicated that the <jats:italic>Terminalia arjuna<\/jats:italic> extract contains constituents that can potentially inhibit the CYP3A and CYP2D isoenzymes which may in turn lead to pharmacokinetic drug\u2013herb interaction.<\/jats:p>","DOI":"10.1002\/bdd.2121","type":"journal-article","created":{"date-parts":[[2018,1,12]],"date-time":"2018-01-12T07:26:38Z","timestamp":1515741998000},"page":"143-151","source":"Crossref","is-referenced-by-count":4,"title":["Bioactivity guided fractionation of methanolic extract of <i>Terminalia arjuna<\/i> for its CYP3A and CYP2D inhibition in rat liver microsomes"],"prefix":"10.1002","volume":"39","author":[{"given":"Alice","family":"Varghese","sequence":"first","affiliation":[{"name":"Shobhaben Pratapbhai Patel School of Pharmacy &amp; Technology Management  SVKM's NMIMS, Vile Parle (W), Mumbai \u2010400056 India"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Prachi","family":"Saboo","sequence":"additional","affiliation":[{"name":"Shobhaben Pratapbhai Patel School of Pharmacy &amp; Technology Management  SVKM's NMIMS, Vile Parle (W), Mumbai \u2010400056 India"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0124-1741","authenticated-orcid":false,"given":"Sarika","family":"Wairkar","sequence":"additional","affiliation":[{"name":"Shobhaben Pratapbhai Patel School of Pharmacy &amp; Technology Management  SVKM's NMIMS, Vile Parle (W), Mumbai \u2010400056 India"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"311","published-online":{"date-parts":[[2018,2,8]]},"reference":[{"key":"e_1_2_7_2_1","doi-asserted-by":"publisher","DOI":"10.1007\/PL00000897"},{"key":"e_1_2_7_3_1","doi-asserted-by":"publisher","DOI":"10.1046\/j.1365-2125.1998.00764.x"},{"key":"e_1_2_7_4_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.ejfs.2012.10.001"},{"key":"e_1_2_7_5_1","unstructured":"Guidance for Industry Drug Interaction Studies\u2010 Study Design Data Analysis Implications for Dosing and Labeling Recommendations 2012.https:\/\/www.fda.gov\/downloads\/%20drugs\/guidances\/ucm292362.pdf"},{"key":"e_1_2_7_6_1","doi-asserted-by":"publisher","DOI":"10.1046\/j.1365-2125.2002.01683.x"},{"key":"e_1_2_7_7_1","doi-asserted-by":"publisher","DOI":"10.2165\/00003495-200565090-00005"},{"key":"e_1_2_7_8_1","doi-asserted-by":"publisher","DOI":"10.2165\/00003495-200161150-00002"},{"issue":"1","key":"e_1_2_7_9_1","first-page":"35","article-title":"Herbal medicine","volume":"78","author":"Kamboj V. P.","year":"2000","journal-title":"Current Science\u2010Bangalore"},{"key":"e_1_2_7_10_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0024-3205(03)00671-4"},{"key":"e_1_2_7_11_1","doi-asserted-by":"publisher","DOI":"10.2174\/0929867033456855"},{"key":"e_1_2_7_12_1","doi-asserted-by":"publisher","DOI":"10.1172\/JCI119439"},{"key":"e_1_2_7_13_1","doi-asserted-by":"publisher","DOI":"10.1001\/archinte.158.20.2200"},{"key":"e_1_2_7_14_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.lfs.2005.12.010"},{"issue":"4","key":"e_1_2_7_15_1","first-page":"281","article-title":"Herbal medicine: current status and the future","volume":"4","author":"Pal S. K.","year":"2003","journal-title":"Asian Pacific Journal of Cancer Prevention"},{"key":"e_1_2_7_16_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.phymed.2003.11.007"},{"key":"e_1_2_7_17_1","doi-asserted-by":"publisher","DOI":"10.1007\/s00204-008-0332-8"},{"key":"e_1_2_7_18_1","doi-asserted-by":"publisher","DOI":"10.1089\/acm.2012.0275"},{"key":"e_1_2_7_19_1","doi-asserted-by":"publisher","DOI":"10.1002\/ptr.2572"},{"issue":"2","key":"e_1_2_7_20_1","first-page":"138","article-title":"In vitro and in vivo evaluation of CYP1a interaction potential of Terminalia arjuna bark","volume":"76","author":"Varghese A.","year":"2014","journal-title":"Indian Journal of Pharmaceutical Sciences"},{"key":"e_1_2_7_21_1","doi-asserted-by":"publisher","DOI":"10.2174\/1872312810666160219121415"},{"key":"e_1_2_7_22_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.toxrep.2015.02.008"},{"issue":"11","key":"e_1_2_7_23_1","first-page":"1514","article-title":"Comparative contribution to dextromethorphan metabolism by cytochrome P450 isoforms in vitro: can dextromethorphan be used as a dual probe for both CYP2D6 and CYP3A activities?","volume":"29","author":"Yu A.","year":"2001","journal-title":"Drug Metabolism and Disposition"},{"key":"e_1_2_7_24_1","doi-asserted-by":"publisher","DOI":"10.1124\/dmd.30.12.1311"},{"key":"e_1_2_7_25_1","doi-asserted-by":"publisher","DOI":"10.1081\/DMR-120028427"}],"container-title":["Biopharmaceutics &amp; Drug Disposition"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1002%2Fbdd.2121","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1002\/bdd.2121","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,9,25]],"date-time":"2023-09-25T14:28:27Z","timestamp":1695652107000},"score":1,"resource":{"primary":{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/10.1002\/bdd.2121"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2018,2,8]]},"references-count":24,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2018,3]]}},"alternative-id":["10.1002\/bdd.2121"],"URL":"https:\/\/doi.org\/10.1002\/bdd.2121","archive":["Portico"],"relation":{},"ISSN":["0142-2782","1099-081X"],"issn-type":[{"value":"0142-2782","type":"print"},{"value":"1099-081X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2018,2,8]]}}}